Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether pramlintide (Symlin) will help to reduce
the frequency and severity of hypoglycemia in individuals who have had gastric bypass
surgery.